Polymorphisms of mismatch repair gene hMLH1 and hMSH2 and risk of gastric cancer in a Chinese population

Oncology Letters

Volumn 3, Issue 3, 2012, Pages 591-598

  Xiao, Xian Qiu ^a   Gong, Wei Da ^b   Wang, Shi Zhi ^c   Zhang, Zheng Dong ^c   Rui, Xiao Ping ^a   Wu, Guo Zhong ^a   Ren, Feng ^d  

^a Department of General Surgery   (China)

^b Cancer Hospital of Yixing   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d Soochow University   (China)

Author keywords

Gastric cancer; hMLH1; hMSH2; Polymorphism

Indexed keywords

PROTEIN MLH1; PROTEIN MSH2;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; CANCER RISK; CHINESE; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENDER; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PERIPHERAL LYMPHOCYTE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; STOMACH CANCER;

EID: 84862919224     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.517     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin 60: 277-300, 2010.
2. Afuwape OO, Irabor DO, Ladipo JK and Ayandipo B: A Review of the Current Profile of Gastric Cancer Presentation in the University College Hospital Ibadan, a Tertiary Health Care Institution in the Tropics. J Gastrointest Cancer Feb, 2011 (Epub ahead of print).
3. Herszényi L and Tulassay Z: Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci 14: 249-258, 2010.
4. Wang W, Li YF, Sun XW, et al: Prognosis of 980 patients with gastric cancer after surgical resection. Chin J Cancer 29: 923-930, 2010.
5. Arkenau HT: Gastric cancer in the era of molecularly targeted agents: current drug development strategies. J Cancer Res Clin Oncol 135: 855-866, 2009.
6. Aarnio M, Sankila R, Pukkala E, et al: Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81: 214-218, 1999.
7. Goecke T, Schulmann K, Engel C, et al: Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC consortium. J Clin Oncol 24: 4285-4292, 2006.
8. Abdel-Rahman WM, Mecklin JP and Peltomaki P: The genetics of HNPCC: application to diagnosis and screening. Crit Rev Oncol Hematol 58: 208-220, 2006.
9. Liu T: Mutational screening of hMLH1 and hMSH2 that confer inherited colorectal cancer susceptibility using denature gradient gel electrophoresis (DGGE). Methods Mol Biol 653: 193-205, 2010.
10. Vasen HF, Stormorken A, Menko FH, et al: MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 19: 4074-4080, 2001.
11. Haghighi MM, Javadi GR, Parivar K, Milanizadeh S, Zali N, Fatemi SR and Zali MR: Frequent MSI mononucleotide markers for diagnosis of hereditary nonpolyposis colorectal cancer. Asian Pac J Cancer Prev 11: 1033-1035, 2010.
12. Scheuner MT, McNeel TS and Freedman AN: Population prevalence of familial cancer and common hereditary cancer syndromes. The 2005 California Health Interview Survey. Genet Med 12: 726-735, 2010.
13. Power DG, Gloglowski E and Lipkin SM: Clinical genetics of hereditary colorectal cancer. Hematol Oncol Clin North Am 24: 837-859, 2010.
14. Sheng X, Zhou HH, Zhou XY, et al: Germline mutation analysis of hPMS2 gene in Chinese families with hereditary nonpolyposis colorectal cancer. World J Gastroenterol 16: 3847-3852, 2010.
15. Corso G, Marrelli D and Roviello F: Familial gastric cancer: update for practice management. Fam Cancer 10: 391-396, 2011.
16. Yamasaki Y, Matsushima M, Tanaka H, et al: Patient with eight metachronous gastrointestinal cancers thought to be hereditary nonpolyposis colorectal cancer (HNPCC). Intern Med 49: 209-213, 2010.
17. Capelle LG, Van Grieken NC, Lingsma HF, et al: Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology 138: 487-492, 2010.
18. Xie J, Guillemette S, Peng M, Gilbert C, Buermeyer A and Cantor SB. An MLH1 mutation links BACH1/FANCJ to colon cancer, signaling, and insight toward directed therapy. Cancer Prev Res (Phila) 3: 1409-1416, 2010.
19. van Roon EH, van Puijenbroek M, Middeldorp A, et al: Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition? BMC Cancer 10: 180, 2010.
20. Allan JM, Shorto J, Adlard J, et al: MLH1 -93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer. Int J Cancer 123: 2456-2459, 2008.
21. Park SH, Lee GY, Jeon HS, et al: -93G-->A polymorphism of hMLH1 and risk of primary lung cancer. Int J Cancer 112: 678-682, 2004.
22. Wang H, Wang Y, Liu H, et al: Polymorphisms in hMLH1 and risk of early-onset lung cancer in a southeast Chinese population. Lung Cancer 59: 164-170, 2008.
23. Vietri MT, Riegler G, De Paola M, et al: I219V polymorphism in hMLH1 gene in patients affected with ulcerative colitis. Genet Test Mol Biomarkers 13: 193-197, 2009.
24. Trojan J, Zeuzem S, Randolph A, et al: Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system. Gastroenterology 122: 211-219, 2002.
25. Bellacosa A: Functional interactions and signaling properties of mammalian DNA mismatch repair proteins. Cell Death Differ 8: 1076-1092, 2001.
26. Jung CY, Choi JE, Park JM, et al: Polymorphisms in the hMSH2 gene and the risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 15: 762-768, 2006.
27. Worrillow LJ, Travis LB, Smith AG, Sara R, Andrew JS and Christopher PW: An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res 9: 3012-3020, 2003.
28. Paz-y-Miño C, Pérez JC, Fiallo BF and Leone PE: A polymorphism in the hMSH2 gene (gIVS12-6T>C) associated with non-Hodgkin lymphomas. Cancer Genet Cytogenet 133: 29-33, 2002.
29. Palicio M, Blanco I, Tórtola S, et al: Intron splice acceptor site polymorphism in the hMSH2 gene in sporadic and familial colorectal cancer. Br J Cancer 82: 535-537, 2000.
30. Goessl C, Plaschke J, Pistorius S, Hahn M, Frank S and Hampl M: An intronic germline transition in the HNPCC gene hMSH2 is associated with sporadic colorectal cancer. Eur J Cancer 33: 1869-1874, 1997.
31. Brentnall TA, Rubin CE, Crispin DA, et al: A germline substitution in the human MSH2 gene is associated with high-grade dysplasia and cancer in ulcerative colitis. Gastroenterology 109: 151-155, 1995.
32. Cheng H, Sun N, Sun X, et al: Polymorphisms in hMSH2 and hMLH1 and response to platinum-based chemotherapy in advanced non-small-cell lung cancer patients. Acta Biochim Biophys Sin (Shanghai) 42: 311-317, 2010.
33. Mrkonjic M, Raptis S, Green RC, et al: MSH2 118T>C and MSH6 159C>T promoter polymorphisms and the risk of colorectal cancer. Carcinogenesis 28: 2575-2580, 2007.
34. Shin KH, Shin JH, Kim JH and Park JG: Mutational analysis of promoters of mismatch repair genes hMSH2 and hMLH1 in hereditary nonpolyposis colorectal cancer and early onset colorectal cancer patients: identification of three novel germ-line mutations in promoter of the hMSH2 gene. Cancer Res 62: 38-42, 2002.
35. Vasen HF, Watson P, Mecklin JP and Lynch HT: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116: 1453-1456, 1999